Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen.
Open Access
- 1 November 1988
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 82 (5) , 1700-1707
- https://doi.org/10.1172/jci113783
Abstract
In five patients with venous thromboembolic disease treated with recombinant tissue-type plasminogen activator (rt-PA), there was a marked increase in the mean concentrations of fibrinopeptide A (from 0.6 to 5.9 nM; P less than 0.0001) and desarginine fibrinopeptide B (from 5.6 nM to 24.1 nM; P less than 0.01) 30 min after a bolus of rt-PA (0.6 mg/kg). Thrombin was unlikely to be responsible because the levels of desarginine fibrinopeptide B exceeded those of fibrinopeptide A and the changes occurred despite concomitant heparin therapy. The purpose of this study therefore, was to determine whether rt-PA directly releases the fibrinopeptides from fibrinogen. Incubation of rt-PA with heparinized plasma or purified fibrinogen resulted in time and dose-dependent release of both fibrinopeptide A and B. Contaminating thrombin was not responsible for this activity by the following criteria: the rate of rt-PA mediated fibrinopeptide B release was considerably faster than that of fibrinopeptide A, and fibrinopeptide release was unaffected by heparin, hirudin, or a monospecific antithrombin IgG. Aprotinin also had no effect on fibrinopeptide release, indicating that this activity was not plasmin mediated. Fibrinopeptide release was shown to be due to rt-PA because this activity was completely blocked by a monoclonal antibody against the enzyme. Further, the specificity of rt-PA for the thrombin cleavage sites on fibrinogen was confirmed by the demonstration that rt-PA released fibrinopeptide A or fibrinopeptide B from fibrinopeptide A or B-containing substrates, respectively. These studies thus demonstrate that (a) rt-PA releases fibrinopeptides A and B from fibrinogen thereby indicating that this enzyme is not specific for plasminogen, and (b) plasma fibrinopeptide A and desarginine fibrinopeptide B levels are not specific markers of thrombin action on fibrinogen in patients receiving rt-PA.This publication has 40 references indexed in Scilit:
- Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.Journal of Clinical Investigation, 1987
- Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.Circulation, 1984
- Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells.Journal of Clinical Investigation, 1984
- Thrombolysis, clot selectivity, and kinetics.Circulation, 1984
- Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions.Circulation, 1984
- Coronary Thrombolysis with Tissue-Type Plasminogen Activator in Patients with Evolving Myocardial InfarctionNew England Journal of Medicine, 1984
- Studies on the kinetics of plasminogen activation by tissue plasminogen activatorBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1982
- Leukocyte Elastase Release during Blood CoagulationJournal of Clinical Investigation, 1982
- Immunochemical studies of human fibrinopeptide A using synthetic peptide homologuesBiochemistry, 1976
- Reactivity of fibrinogen and fibrinopeptide A containing fibrinogen fragments with antisera to fibrinopeptide ABiochemistry, 1976